CCL18: a urinary marker of Gaucher cell burden in Gaucher patients
- PMID: 16736095
- DOI: 10.1007/s10545-006-0318-8
CCL18: a urinary marker of Gaucher cell burden in Gaucher patients
Abstract
Glucosylceramide-laden tissue macrophages in Gaucher patients secrete large quantities of chitotriosidase and CC chemokine ligand 18 (CCL18), resulting in markedly increased plasma levels. We have comparatively investigated the occurrence of both parameters in plasma and urine samples of Gaucher patients. Chitotriosidase was high in urine samples of some symptomatic patients, but elevations did not correlate with increased plasma concentrations. Urinary chitotriosidase was particularly high in a patient with severe kidney involvement and local storage cell infiltration. Urinary levels of CCL18 were also highly elevated in samples from Gaucher patients as compared to controls. The median value of the CCL18/creatinine ratio in urine samples of 31 Gaucher patients was 143.3 pg/micromol (range 32-551) and in those of 12 normal subjects was 4.1 pg/micromol (range 1.3-6.8). In sharp contrast to chitotriosidase, increases in the low-molecular-mass chemokine CCL18 in urine and plasma specimens of Gaucher patients correlated well. A correlation was also observed for reductions in urinary and plasma CCL18 following therapy. It is concluded that assessment of urinary CCL18 of Gaucher patients gives insight into the total body burden on Gaucher cells, whereas that of chitotriosidase does not. Urinary chitotriosidase appears rather to be a reflection of renal pathology.
Similar articles
-
Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention.Blood. 2004 Jan 1;103(1):33-9. doi: 10.1182/blood-2003-05-1612. Epub 2003 Sep 11. Blood. 2004. PMID: 12969956
-
Plasma chitotriosidase and CCL18 as surrogate markers for granulomatous macrophages in sarcoidosis.Clin Chim Acta. 2010 Jan;411(1-2):31-6. doi: 10.1016/j.cca.2009.09.034. Epub 2009 Oct 4. Clin Chim Acta. 2010. PMID: 19808030
-
Elevated plasma chemokine CCL18/PARC in beta-thalassemia.Blood Cells Mol Dis. 2005 Nov-Dec;35(3):328-31. doi: 10.1016/j.bcmd.2005.07.006. Epub 2005 Aug 31. Blood Cells Mol Dis. 2005. PMID: 16137900
-
Identification and use of biomarkers in Gaucher disease and other lysosomal storage diseases.Acta Paediatr Suppl. 2005 Mar;94(447):43-6; discussion 37-8. doi: 10.1111/j.1651-2227.2005.tb02110.x. Acta Paediatr Suppl. 2005. PMID: 15895711 Review.
-
Accuracy of chitotriosidase activity and CCL18 concentration in assessing type I Gaucher disease severity. A systematic review with meta-analysis of individual participant data.Haematologica. 2021 Feb 1;106(2):437-445. doi: 10.3324/haematol.2019.236083. Haematologica. 2021. PMID: 32001533 Free PMC article.
Cited by
-
Laboratory and genetic evaluation of Gaucher disease.Wien Med Wochenschr. 2010 Dec;160(23-24):600-4. doi: 10.1007/s10354-010-0814-1. Epub 2010 Aug 16. Wien Med Wochenschr. 2010. PMID: 20714811 Review.
-
Optimal therapy in Gaucher disease.Ther Clin Risk Manag. 2010 Jul 21;6:315-23. doi: 10.2147/tcrm.s6955. Ther Clin Risk Manag. 2010. PMID: 20668714 Free PMC article.
-
Gpnmb Is a Potential Marker for the Visceral Pathology in Niemann-Pick Type C Disease.PLoS One. 2016 Jan 15;11(1):e0147208. doi: 10.1371/journal.pone.0147208. eCollection 2016. PLoS One. 2016. PMID: 26771826 Free PMC article.
-
Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease.Drug Des Devel Ther. 2015 Aug 18;9:4639-47. doi: 10.2147/DDDT.S77760. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26345314 Free PMC article. Review.
-
Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring.J Inherit Metab Dis. 2008 Jun;31(3):319-36. doi: 10.1007/s10545-008-0779-z. Epub 2008 May 23. J Inherit Metab Dis. 2008. PMID: 18509745 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical